Thyroid nodules are a common clinical illness. Neck ultrasonography identifies at least one nodule in 20-76 % of adults, the majority of which are benign. [1] [2] [3] Cytopathologic evaluation by ultrasound-guided fine needle aspiration (FNA) has emerged as the principal means to evaluate malignancy risk, and is recommended for most nodules greater than 1-1.5 cm.
microarray platform for this test demonstrated excellent reproducibility and stability in different temperatures and shipping environments. 19 Here, we discuss the multicenter validation trial and subsequent published experiences with the Afirma GEC.
Validation and Clinical Use of the Afirma Gene Expression Classifier
In 2012, the New England Journal of Medicine (NEJM) published the results of a prospective, multicenter, blinded validation of the Afirma GEC in 3,789 patients enrolled from 49 academic and community sites. 20 Of 265 indeterminate nodules greater than 1 cm for which surgery was performed and gold-standard histopathology available for blinded review, 85 (32 %) nodules were malignant and 180 benign.
The Afirma GEC demonstrated a sensitivity of 92 % (95 % confidence interval [CI] 84-97 %) and specificity of 52 % (95 % CI 44-59 %). In a population harboring a malignancy prevalence of 32 %, the negative predictive value (NPV) and positive predictive value (PPV) were 93 % and 47 %, respectively. More specifically, when Bethesda categories were AUS/FLUS or FN, the NPV for the Afirma GEC was 95 % and 94 %, respectively-similar to that of a benign cytology diagnosis for which conservative management is often favored. The NPV was 85 % for SUSP nodules and, at present, the Afirma GEC is not recommended for routine use in this population.
In spite of the demonstrated accuracy of this testing approach to identify benign nodules preoperatively, it remained unclear how implementation of this knowledge could affect clinical practice and vary in a real-world environment.
To address this concern, a multicenter experience with the Afirma GEC Central to the interpretation of Afirma GEC performance is the relationship between the prevalence of thyroid cancer in the population studied (i.e. pretest probability), and the NPV and PPV of a test. As the prevalence of malignancy increases, the NPV falls since there is an increasing probability that a negative test result represents a false negative. As the malignancy rate declines, NPV improves as the test result is increasingly likely to be a true negative. Differences in the underlying rate of malignant nodules within a population and the specific malignancy risk within nodules classified as indeterminate will influence both NPV and PPVs. Prior studies have confirmed substantial inter-and intra-rater variability for indeterminate cytology, even among experts 25-27 using the Bethesda system. Thus, the interpretation of an Afirma GEC result must be performed in the context of the thyroid cancer prevalence within a given practice setting. has not yet been performed. 34 The 17 
